Evaluation of the Effect of Time of Administration on the Activity on First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial (IMMUNOTIME)
IMMUNOTIME is a French multicenter randomised phase III trial in patients with metastatic non-squamous non-small cell lung cancer starting first-line treatment with pembrolizumab, carboplatin and pemetrexed. Patients receive the standard regimen and are randomised to start their pembrolizumab infusions either in the morning (08:00-12:00) or in the afternoon (13:00-17:00). The trial aims to determine whether morning administration improves survival at one year. A total of 242 patients will be included in 33 centres.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Pembrolizumab combined with carboplatin and pemetrexed is the standard first-line treatment for metastatic non-squamous NSCLC without EGFR, or ALK activation. Several immune functions involved in the response to anti-PD-1 therapy follow a circadian rhythm, including T-cell activity, tumour infiltration by dendritic cells and PD-1 expression. Retrospective studies in more than 1,600 patients treated with immune checkpoint inhibitors have reported longer progression-free and overall survival when treatment was given earlier in the day. In a meta-analysis of 782 NSCLC patients, the hazard ratio for death was 0.53 (95% CI 0.34-0.80). More recently, a retrospective cohort of 713 NSCLC patients treated with pembrolizumab plus chemotherapy showed markedly longer overall survival with morning infusions. No randomised trial has yet addressed this question.
IMMUNOTIME is an open-label, randomised (1:1), multicentre superiority trial. Eligible patients are adults with stage IV non-squamous NSCLC, ECOG performance status 0 or 1, known PD-L1 status, at least one measurable lesion and no indication for targeted therapy. Patients previously treated with immunotherapy, receiving immunosuppressive treatment or with an autoimmune disease at risk of severe flare are not eligible.
Randomisation is stratified by centre, sex, performance status and PD-L1 expression (<1%, 1-49%, ≥50%). In both groups, treatment is given every 21 days and follows routine practice: pembrolizumab 200 mg followed by pemetrexed 500 mg/m² and carboplatin AUC 5 for 4 cycles, then pembrolizumab and pemetrexed maintenance (for up to two years, as in standart care). The only study intervention is the time of the pembrolizumab infusion, which starts between 08:00 and 12:00 in the morning group and between 13:00 and 17:00 in the afternoon group during the first year. Each patient keeps the same time slot (±1 hour) throughout treatment.
The primary endpoint is the 1-year survival rate. Secondary endpoints include: progression-free survival, overall survival, best and early tumour response (RECIST), time to treatment discontinuation, toxicity (CTCAE v5.0), quality of life (EQ-5D, EORTC QLQ-C30), sleep quality (PSQI), chronotype (Horne-Östberg questionnaire) and cost-utility. Survival will also be analysed according to the actual time of infusion, in order to model the optimal timing.
Three optional ancillary studies will explore circadian biomarkers of response and tolerance: home monitoring with a wearable sensor and nocturnal polygraphy in about 50 patients, pembrolizumab pharmacokinetics, cytokines and circulating immune cells, clock gene expression in tumour and blood samples
The 242 patients will be recruited over 18 months. Each patient takes part for up to 25 months, including one year of treatment and one year of follow-up, and the trial will last 43 months in total. The primary analysis will be performed in the intention-to-treat population. An independent Data Safety Monitoring Board will oversee the trial. The sponsor is Assistance Publique - Hôpitaux de Paris, and the trial is funded by the PHRC-K programme.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 3
連絡先と場所
研究連絡先
研究連絡先
- 名前：Boris DUCHEMANN, Dr
- 電話番号：+33 01.48.95.50.33
- メール：boris.duchemann@aphp.fr
研究場所
-
-
Auvergne-Rhône-Alpes
-
Aurillac、Auvergne-Rhône-Alpes、フランス、15000
- CH Henri Mondor - Service d'oncologie
-
コンタクト：
- Daniela BURLACU, Dr
- 電話番号：+33 04.71.46.56.56
- メール：d.burlacu@ch-aurillac.fr
-
Bron、Auvergne-Rhône-Alpes、フランス、69500
- Hôpital Louis Pradel [HCL] - Service de pneumologie
-
コンタクト：
- Thomas PIERRET, Dr
- 電話番号：+33 04.27.85.77.00
- メール：thomas.pierret@chu-lyon.fr
-
-
Bouches-du-Rhône
-
Marseille、Bouches-du-Rhône、フランス、13915
- Hôpital Nord [AP-HM] - Service d'oncologie multidisciplinaire et innovations thérapeutiques
-
コンタクト：
- Laurent GREILLIER, Pr
- 電話番号：+33 04.91.96.59.01
- メール：laurent.greillier@ap-hm.fr
-
-
Calvados
-
Bayeux、Calvados、フランス、14400
- CH Aunay-Bayeux - Service d'oncologie
-
コンタクト：
- Pierre-Emmanuel BRACHET, Dr
- 電話番号：+33 02.31.51.54.17
- メール：pe.brachet@ch-ab.fr
-
Caen、Calvados、フランス、14076
- Centre François Baclesse - Service de pneumologie
-
コンタクト：
- Hubert CURCIO, Dr
- 電話番号：+33 02.31.45.50.50
- メール：h.curcio@baclesse.unicancer.fr
-
-
Hauts-de-Seine
-
Suresnes、Hauts-de-Seine、フランス、92150
- Hôpital Foch - Service d'oncologie médicale
-
-
Ile-et-Vilaine
-
Rennes、Ile-et-Vilaine、フランス、35033
- CHU de Rennes, Hôpital Pontchaillou - Service de pneumologie
-
コンタクト：
- Léa HERVE, Dr
- 電話番号：+33 02.99.28.37.38
- メール：herve.lena@chu.rennes.fr
-
-
Maine-et-Loire
-
Angers、Maine-et-Loire、フランス、49933
- CHU d'Angers - Service de pneumologie
-
コンタクト：
- Grégoire JUSTEAU, Dr
- 電話番号：+33 02.41.35.58.44
- メール：Gregoire.justeau@chu-angers.fr
-
-
Nord
-
Lille、Nord、フランス、59037
- CHU Lille - Service de pneumologie et d'oncologie thoracique
-
コンタクト：
- Arnaud SCHERPEREEL, Pr
- 電話番号：+33 03.20.44.49.98
- メール：arnaud.scherpereel@chu-lille.fr
-
-
Paris 14
-
Paris、Paris 14、フランス、75014
- Hôpital Cochin [AP-HP] - Service de pneumologie, Unité oncologie thoracique
-
コンタクト：
- Marie WISLEZ, Pr
- 電話番号：+33 01.58.41.18.89
- メール：marie.wislez@aphp.fr
-
Paris、Paris 14、フランス、75014
- Hôpital Paris Saint Joseph - Service de pneumo-oncologie et d'allergologie
-
コンタクト：
- Charles NALTET, Dr
- 電話番号：+33 01.44.12.37.52
- メール：cnaltet@ghpsj.fr
-
-
Paris 15
-
Paris、Paris 15、フランス、75015
- Hôpital Européen Georges Pompidou [APHP] - Service d'oncologie thoracique
-
コンタクト：
- Elizabeth FABRE, Dr
- 電話番号：+33 01.56.09.53.71
- メール：elizabeth.fabre@aphp.fr
-
-
Pyrénées-Atlantiques
-
Bayonne、Pyrénées-Atlantiques、フランス、64100
- CH de la Côte Basque - Service de pneumologie médicale
-
コンタクト：
- Sophie SCHNEIDER, Dr
- 電話番号：+33 05.59.44.38.85
- メール：sschneider@ch-cotebasque.fr
-
-
Saint-Maur-des-Faussés
-
Créteil、Saint-Maur-des-Faussés、フランス、94010
- CHI de Créteil - Service de pneumologie
-
コンタクト：
- Gaëlle ROUSSEAU-BUSSAC, Dr
- 電話番号：+33 01.57.02.21.01
- メール：gaelle.rousseaubussac@chicreteil.fr
-
-
Seine-Saint-Denis
-
Bobigny、Seine-Saint-Denis、フランス、93000
- CH d'Avicenne [AP-HP] - Service d'oncologie médicale et thoracique
-
コンタクト：
- Boris DUCHEMANN, Dr
- 電話番号：+33 01.48.95.50.33
- メール：boris.duchemann@aphp.fr
-
Montfermeil、Seine-Saint-Denis、フランス、93370
- GHI Le Raincy Montfermeil - Service d'oncologie
-
コンタクト：
- Thierry COLLON, Dr
- 電話番号：+33 01.41.70.80.00
- メール：thierry.collon@ght-gpne.fr
-
-
Val-de-Marne
-
Villejuif、Val-de-Marne、フランス、94800
- Hôpital Paul-Brousse [AP-HP] - Service d'oncologie digestive et médicale
-
コンタクト：
- Pascal HAMMEL, Pr
- 電話番号：+33 01.45.59.65.32
- メール：pascal.hammel@aphp.fr
-
Villejuif、Val-de-Marne、フランス、94805
- Hôpital Gustave Roussy - Service d'oncologie médicale
-
コンタクト：
- Benjamin BLESSE, Pr
- 電話番号：+33 01.42.11.43.41
- メール：benjamin.besse@gustaveroussy.fr
-
-
Var
-
Toulon、Var、フランス、83000
- CHITS Hôpital Sainte Musse
-
コンタクト：
- Clarisse AUDIGIER VALETTE, Dr
- 電話番号：+33 04.94.14.56.10
- メール：Clarisse.audigier-valette@ch-toulon.fr
-
-
Yvelines
-
Le Chesnay、Yvelines、フランス、78157
- CH de Versailles, Hôpital André Mignot - Service de pneumologie
-
コンタクト：
- Cécile Dr DUJON, Dr
- 電話番号：+33 01.39.63.88.88
- メール：cdujon@ght78sud.fr
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- 1 Have a histologically-confirmed or cytologically confirmed diagnosis of stage IV (M1a or M1b- AJCC 7th edition) non-squamous NSCLC.
- 2. Have confirmation that EGFR or ALK-directed therapy is not indicated (documentation of absence of tumor activating EGFR mutations AND absence of ALK gene rearrangements) OR presence of a K-Ras mutation.
- 3. Have measurable disease based on RECIST 1.1 as determined by the local site investigator/radiology assessment. Target lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
- 4. Have not received prior systemic treatment for their advanced/metastatic NSCLC.
Subjects who received adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease.
-
5. Have provided tumor tissue from locations not radiated prior to biopsy; formalin fixed specimens after the subject has been diagnosed with metastatic disease will be preferred for determination of PD-L1 status prior to randomisation. Biopsies obtained prior to receipt of adjuvant/neoadjuvant chemotherapy will be permitted if recent biopsy is not feasible.
-
6. Be ≥18 years of age on the day of signing informed consent.
-
7. Have a life expectancy of at least 3 months.
-
8. Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.
-
9. Have adequate organ function as indicated by the following laboratory values :
- Hematological Absolute neutrophil count (ANC) ≥ 1,500 /mcL
- Platelets Hemoglobin (4 weeks without transfusions) ≥ 100,000 / mcL ≥ 9.0 g/dL or ≥ 5.6 mmol/L
- Renal calculated creatinine clearance (CrCl)a ≥ 50 mL/min
- Hepatic Serum total bilirubin ≥ 50 mL/min ≤ 1.5xULN Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5xULN
- AST (SGOT) and ALT (SGPT) ≤ 2.5xULN or ≤ 5xULN for subjects with liver metastases
- Coagulation International Normalized Ratio (INR) or Prothrombin Time (PT) / Activated Partial Thromboplastin Time (aPTT) or Partial Thromboplastin Time (PTT) ≤ 1.5xULN unless the subject is receiving anticoagulant therapy
- Creatinine Clearance should be calculated using the Cockcroft-Gault Method
-
10. If female of childbearing potential*, be willing to use an adequate method of contraception, for the course of the study through 120 days after the last dose of study medication or through 180 days after last dose of chemotherapeutic agents as specified in the protocol. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
-
11. If male subject with a female partner(s) of child-bearing potential, must agree to use an adequate method of contraception. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
-
12. Subject has voluntarily agreed to participate by giving written informed consent/assent for the trial. The subject may also provide consent/assent for exploratory studies. However, the subject may participate in the main trial without participating in exploratory studies.
-
13. Affiliation to French social security system
- A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
Exclusion Criteria:
The patient will not be included in the trial if he or she:
-
1. Has predominantly squamous cell histology NSCLC. Mixed tumors will be categorized by the predominant cell type; if small cell elements are present, the subject is ineligible.
-
2. Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to administration of pembrolizumab.
-
3. Before the first dose of trial treatment:
- Has received prior systemic cytotoxic chemotherapy for metastatic disease
- Has received antineoplastic biological therapy (e.g., erlotinib, crizotinib, cetuximab)
- Had major surgery
-
4. Received radiation therapy to the lung that is > 30 Gy within 6 months of the first dose of trial treatment.
-
5. Completed palliative radiotherapy within 7 days of the first dose of trial treatment.
-
6. Is expected to require any other form of antineoplastic therapy while on study.
-
7. Has received a live-virus vaccination within 30 days of planned treatment start.
Seasonal flu vaccines that do not contain live virus are permitted.
- 8. Has clinically active diverticulitis, intra-abdominal abscess, GI obstruction, abdominal carcinomatosis.
- 9. Has a known history of prior malignancy except if the subject has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy. Note: The time requirement for no evidence of disease for 5 years does not apply to the NSCLC tumor for which a subject is enrolled in the study. The time requirement also does not apply to subjects who underwent successful definitive resection of basal cell carcinoma of the skin, superficial bladder cancer, squamous cell carcinoma of the skin, in situ cervical cancer, or other in situ cancers
- 10. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are clinically stable for at least 2 weeks and, have no evidence of new or enlarging brain metastases and also are off steroids 3 days prior to dosing with study medication. Stable brain metastases by this definition should be established prior to the first dose of study medication. Subjects with asymptomatic brain metastases (i.e., no neurological symptoms, no requirements for corticosteroids, and no lesion >1.5 cm) may participate but will require regular imaging of the brain as a site of disease.
- 11. Previously had a severe hypersensitivity reaction to treatment with another mAb.
- 12. Has a known sensitivity to any component of carboplatin or pemetrexed
- 13. Contraindication to investigational medicinal products or to auxiliary medicinal products
- 14. Has active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- 15. Is on chronic systemic steroids. Subjects with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections would not be excluded from the study.
- 16. Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤ 1.3 g per day, for a 5-day period (8-day period for longacting agents, such as piroxicam).
- 17. Is unable or unwilling to take folic acid or vitamin B12 supplementation.
- 18. Had prior treatment with any other anti-PD-1, or PD-L1 or PD-L2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms. Has participated in any other MK-3475 trial and has been treated with MK-3475. Examples of such antibodies include (but are not limited to) antibodies against IDO, PD-L1, IL-2R, GITR
- 19. Has an active infection requiring therapy.
- 20. Has known history of Human Immunodeficiency Virus (HIV) (known HIV 1/2 antibodies positive).
- 21. Has known active Hepatitis B or C. Active Hepatitis B is defined as a known positive HBsAg result. Active Hepatitis C is defined by a known positive Hep C Ab result and known quantitative HCV RNA results greater than the lower limits of detection of the assay.
- 22. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating Investigator.
- 23. Has known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial.
- 24. Has interstitial lung disease or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management. Lymphangitic spread of the NSCLC is not exclusionary.
- 25. Is pregnant or breastfeeding, or expecting to conceive or father children with in the projected duration of the study
- 26. Patients under AME
- 27. Adults subject to a legal measure protection (guardianship, curatorship and safeguard of justice)
- 28. Patients deprived of their liberty by a judicial or administrative decision
- Secondary exclusion criterion: If female of childbearing potential, have a positive urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：処理
- 割り当て：ランダム化
- 介入モデル：並列代入
- マスキング：なし（オープンラベル）
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的：Early time of administration
Chemoimmunotherapy in the early time of administration group (9:00-12:00) |
Main intervention. Chemoimmunitherapy used as standart care. Questionnaires EORTC-QLQ C30, EuroQol(EQ)-5D (quality of life) and Puttsburgh (Sleep quality) are realised before 1st Cycle, and at cycle 4, 8, 12 and 16 Questionnaire Hörne-Ostberg (Chronotype) is realised before 1st Cycle, and at cycle 4, 8 Auto-Samples: Before C1 (Day 1: 3 x saliva tubes ; Day 2: 3 x saliva tubes) to determine cortisol concentration Device ( Multisense® Product - RDS) Before C1 (3 to 7 days before), after C2 (3 to 7 days after) to collect physiological parameters Samples: C1 (4 x 10 ml blood tubes), C2 (4 x 10ml blood tubes), C3 (2 x 10 ml blood tubes) et C4 (2 x 10ml blood tubes) Pharmacokinetics of Pembrolizumab observation Cytokines, soluble and exosomal PDL-1 serum concentrations exploration Immunomonitoring of circulating immune populations Samples: C1 (1 x 10 ml blood tubes), C2 (1 x 10ml blood tubes) Analysis of global transcriptomic datasets to estimate the proportions of immune cells in the sample, as a possible marker of tumour immune infiltration, Analysis of global RNAseq data from patients to estimate the composition of immune cell types. |
|
アクティブコンパレータ：Late time of administration
Chemoimmunotherapy late time of administration group (13:00 - 17:00) |
Main intervention. Chemoimmunitherapy used as standart care. Questionnaires EORTC-QLQ C30, EuroQol(EQ)-5D (quality of life) and Puttsburgh (Sleep quality) are realised before 1st Cycle, and at cycle 4, 8, 12 and 16 Questionnaire Hörne-Ostberg (Chronotype) is realised before 1st Cycle, and at cycle 4, 8 Auto-Samples: Before C1 (Day 1: 3 x saliva tubes ; Day 2: 3 x saliva tubes) to determine cortisol concentration Device ( Multisense® Product - RDS) Before C1 (3 to 7 days before), after C2 (3 to 7 days after) to collect physiological parameters Samples: C1 (4 x 10 ml blood tubes), C2 (4 x 10ml blood tubes), C3 (2 x 10 ml blood tubes) et C4 (2 x 10ml blood tubes) Pharmacokinetics of Pembrolizumab observation Cytokines, soluble and exosomal PDL-1 serum concentrations exploration Immunomonitoring of circulating immune populations Samples: C1 (1 x 10 ml blood tubes), C2 (1 x 10ml blood tubes) Analysis of global transcriptomic datasets to estimate the proportions of immune cells in the sample, as a possible marker of tumour immune infiltration, Analysis of global RNAseq data from patients to estimate the composition of immune cell types. |
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Survival rate
時間枠：At one year (12 months)
|
Survival rate is defined as the survival probability at one year. |
At one year (12 months)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression Free Survival (PFS)
時間枠：Until all-cause death or tumor progression (monitored throughout the 24 months of the patient's participation)
|
PFS is defined as delay from randomisation until all-cause death or tumor progression whichever comes first |
Until all-cause death or tumor progression (monitored throughout the 24 months of the patient's participation)
|
|
Overall Survival (OS)
時間枠：from randomisation until all-cause death (monitored throughout the 24 months of the patient's participation)
|
Overall Survival (OS) defined as delay from randomisation until all-cause death. |
from randomisation until all-cause death (monitored throughout the 24 months of the patient's participation)
|
|
Tumor respons
時間枠：Over 1 year, and early response rate at 6 weeks from randomisation
|
Best tumor response rate and early response rate according to RECIST criteria |
Over 1 year, and early response rate at 6 weeks from randomisation
|
|
Safety
時間枠：Up to two years (28 months)
|
Adverse events categorized by severity and type, rated following CTCAE v.5.0 |
Up to two years (28 months)
|
|
Quality of Life Index 1
時間枠：At the 16th cycle after randomization (48 weeks)
|
Quality of life according to the EQ-5D-5L test results |
At the 16th cycle after randomization (48 weeks)
|
|
Quality of Life Index 2
時間枠：At the 16h cycle after randomization (48 weeks)
|
Quality of life according to the EORTC QLQ C30 test results |
At the 16h cycle after randomization (48 weeks)
|
|
Quality of sleep index
時間枠：At the 16th cycle after randomization (48 weeks)
|
Quality of sleep according to the Pittsburgh test results |
At the 16th cycle after randomization (48 weeks)
|
|
Chronotype assessment
時間枠：At the 8th cycle after randomization (24 weeks)
|
Chronotype assesssments according to the Hörne-Ostberg test results |
At the 8th cycle after randomization (24 weeks)
|
|
Cost-Utility
時間枠：Up to two years (28 months)
|
Health economics analysis, in particular through associated healthcare costs, additional GP or specialist consultations, and complementary treatments. |
Up to two years (28 months)
|
|
Facultative Result (Exploratory study)
時間枠：Up to two years (28 months)
|
Optimal time of administration through mathematical modelling |
Up to two years (28 months)
|
協力者と研究者
捜査官
捜査官
- 主任研究者：Boris DUCHEMANN, Dr、Research unit : CCT Chronothérapie, cancers et transplantation - Hospital Avicenne, Assistance publique des hôpitaux de Paris - Université Paris Saclay
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- APHP241011
- 2025 (米国 NIH グラント/契約)
- 2025-521891-78-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。